Recent Quotes (30 days)

You have no recent quotes
chg | %

CARDIOME PHARMA CORP  

(Public, NASDAQ:CRME)   Watch this stock  
Find more results for CRME
1.90
0.00 (0.26%)
Real-time:   10:48AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.84 - 1.92
52 week 1.82 - 4.84
Open 1.90
Vol / Avg. 4,991.00/93,708.00
Mkt cap 64.44M
P/E     -
Div/yield     -
EPS -0.82
Shares 33.80M
Beta 1.08
Inst. own 138%
Sep 11, 2017
Cardiome Pharma Corp at Rodman & Renshaw Global Investment Conference
Aug 10, 2017
Cardiome Pharma Corp at Canaccord Genuity Growth Conference
Aug 8, 2017
Q2 2017 Cardiome Pharma Corp Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -147.93% -77.68%
Operating margin -110.97% -63.17%
EBITD margin - -45.80%
Return on average assets -52.90% -34.04%
Return on average equity -119.72% -72.72%
Employees 120 -
CDP Score - -

Address

1441 Creekside Dr 6th Floor
VANCOUVER, BC V6J 4S7
Canada
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Officers and directors

W. James O'Shea Independent Chairman of the Board
Bio & Compensation  - Reuters
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Justin A. Renz Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Sheila M. Grant Chief Operating Officer
Bio & Compensation  - Reuters
David D. McMasters J.D. Corporate General Counsel
Bio & Compensation  - Reuters
David C. Dean Chief Business Development Officer
Bio & Compensation  - Reuters
Jennifer Archibald CPA Chief Business Operations Officer
Bio & Compensation  - Reuters
Hugues Sachot Chief Commercial Officer
Bio & Compensation  - Reuters
Richard M. Glickman LL.D. Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark H.N. Corrigan M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters